The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study.

MLA

Goldman, Adam, et al. “The Real-World Safety Profile of Sodium-Glucose Co-Transporter-2 Inhibitors among Older Adults (≥ 75 Years): A Retrospective, Pharmacovigilance Study.” Cardiovascular Diabetology, vol. 22, no. 1, Jan. 2023, p. 16. EBSCOhost, https://doi.org/10.1186/s12933-023-01743-5.

APA

Goldman, A., Fishman, B., Twig, G., Raschi, E., Cukierman-Yaffe, T., Moshkovits, Y., Pomerantz, A., Ben-Zvi, I., Dankner, R., & Maor, E. (2023). The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study. Cardiovascular Diabetology, 22(1), 16. https://doi.org/10.1186/s12933-023-01743-5

Chicago

Goldman, Adam, Boris Fishman, Gilad Twig, Emanuel Raschi, Tali Cukierman-Yaffe, Yonatan Moshkovits, Alon Pomerantz, Ilan Ben-Zvi, Rachel Dankner, and Elad Maor. 2023. “The Real-World Safety Profile of Sodium-Glucose Co-Transporter-2 Inhibitors among Older Adults (≥ 75 Years): A Retrospective, Pharmacovigilance Study.” Cardiovascular Diabetology 22 (1): 16. doi:10.1186/s12933-023-01743-5.